A document from the National Institute for Health and Care Excellent (NICE) has not recommended Keytruda (pembrolizumab) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumors express PD-L1 with a combined positive score of one or more.
The NICE’s appraisal consultation document asks that the immuno-oncology drug’s manufacturer, Merck & Co (NYSE: MRK), submits further evidence despite the KEYNOTE-048 study showing that its use with chemotherapy or on its own extended survival compared with the standard ‘extreme’ chemotherapy currently used as a first treatment option.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze